Background
==========

Tuberculosis (TB) drug research and development has witnessed resurgence in recent times primarily due to the high mortality rates despite the availability of front line drugs and a prominent BCG vaccine. Synergy of TB with HIV is another factor which has warranted a search for newer therapeutic interventions. Treatment of latent TB infection is also the need of the hour. Iron acquisition is an important virulence mechanism of *Mycobacterium tuberculosis* (MTB). To scavenge iron, bacterial species have developed high affinity, low molecular weight iron chelators termed as siderophores. To counteract the detrimental effect of microbial iron acquisition systems, the host secretes a 21kDa lipocalin protein (Siderocalin) that binds with these iron laden siderophores in an attempt to restrict the growth of MTB within host macrophages.

Methods
=======

In the current study, using molecular docking tools, we assessed the interactions of host Siderocalin with Mycobactin, Parabactin and Cepabactin structurally non similar siderophores from three different bacterial species-MTB, Paracoccus and *Burkholderia cepacia*. A comparison of molecular level interactions of Siderocalin with these siderophores was performed.

Results
=======

Siderocalin forms energetically favourable and stable complexes with parabactin and cepabactin. However the unfavourable positive binding energies for mycobactin- a salicylate derived MTB siderophore indicated that siderocalin does not dock well with mycobactin.

Conclusion
==========

Siderocalin probably fails to disrupt the role of mycobactin in acquiring iron for mycobacteria thereby helping the pathogen to survive leading to progression of disease.
